These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 4040958)
1. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. Stewart DJ; Mikhael NZ; Nanji AA; Nair RC; Kacew S; Howard K; Hirte W; Maroun JA J Clin Oncol; 1985 Sep; 3(9):1251-6. PubMed ID: 4040958 [TBL] [Abstract][Full Text] [Related]
2. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Stewart DJ; Dulberg C; Molepo JM; Mikhael NZ; Montpetit VA; Redmond MD; Goel R Cancer Chemother Pharmacol; 1994; 34(1):14-22. PubMed ID: 8174197 [TBL] [Abstract][Full Text] [Related]
3. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947 [TBL] [Abstract][Full Text] [Related]
4. Platinum accumulation in the kidney and changes in creatinine clearance following chemotherapy with cisplatin in humans. Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Kamura T; Nakano H; Sueishi K Urol Int; 1993; 51(2):57-61. PubMed ID: 8351755 [TBL] [Abstract][Full Text] [Related]
5. [An autopsy case of rectal cancer receiving cisplatin at total dose of 3.250 mg and platinum concentrations in autopsy tissue samples]. Ishigaki H; Satoh S; Saitoh S; Yoshida Y; Ebina T; Satoh T; Nara K; Asano M; Oh-ishi S; Satoh F Gan To Kagaku Ryoho; 1989 Dec; 16(12):3805-8. PubMed ID: 2596863 [TBL] [Abstract][Full Text] [Related]
6. Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations. Nanji AA; Mikhael NZ; Stewart DJ Arch Intern Med; 1985 Nov; 145(11):2013-4. PubMed ID: 4062451 [TBL] [Abstract][Full Text] [Related]
7. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Campbell AB; Kalman SM; Jacobs C Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731 [TBL] [Abstract][Full Text] [Related]
8. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Sueishi K Int Urol Nephrol; 1993; 25(3):215-20. PubMed ID: 8225820 [TBL] [Abstract][Full Text] [Related]
9. Platinum concentrations in human autopsy tumor samples. Stewart DJ; Mikhael NZ; Nair RC; Kacew S; Montpetit V; Nanji A; Maroun JA; Howard K Am J Clin Oncol; 1988 Apr; 11(2):152-8. PubMed ID: 3358362 [TBL] [Abstract][Full Text] [Related]
10. Intracellular metabolites of cisplatin in the rat kidney. Mistry P; Lee C; McBrien DC Cancer Chemother Pharmacol; 1989; 24(2):73-9. PubMed ID: 2731314 [TBL] [Abstract][Full Text] [Related]
12. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. Reece PA; Stafford I; Russell J; Khan M; Gill PG J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171 [TBL] [Abstract][Full Text] [Related]
13. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II). Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076 [TBL] [Abstract][Full Text] [Related]
14. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Vermorken JB; van der Vijgh WJ; Klein I; Gall HE; van Groeningen CJ; Hart GA; Pinedo HM Clin Pharmacol Ther; 1986 Feb; 39(2):136-44. PubMed ID: 3943271 [TBL] [Abstract][Full Text] [Related]
16. Renal excretion of magnesium and trace elements during cisplatin treatment. Zumkley H; Bertram HP; Preusser P; Kellinghaus H; Straub C; Vetter H Clin Nephrol; 1982 May; 17(5):254-7. PubMed ID: 7201366 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452 [TBL] [Abstract][Full Text] [Related]
18. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. Ormond PM; Basinger MA; Jones MM; Hande KR J Pharmacol Exp Ther; 1992 Jul; 262(1):246-51. PubMed ID: 1385629 [TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews. Eiseman JL; Beumer JH; Rigatti LH; Strychor S; Meyers K; Dienel S; Horn CC Cancer Chemother Pharmacol; 2015 Jan; 75(1):143-52. PubMed ID: 25398697 [TBL] [Abstract][Full Text] [Related]
20. Reduction of cisplatin-induced nephrotoxicity in vivo by selenomethionine: the effect on cisplatin-DNA adducts. García Sar D; Montes-Bayón M; Blanco González E; Sierra Zapico LM; Sanz-Medel A Chem Res Toxicol; 2011 Jun; 24(6):896-904. PubMed ID: 21491944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]